Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors.

Nature communications - 9 May 2022

Beyett Tyler S, To Ciric, Heppner David E, Rana Jaimin K, Schmoker Anna M, Jang Jaebong, De Clercq Dries J H, Gomez Gabriel, Scott David A, Gray Nathanael S, Jänne Pasi A, Eck Michael J

Abstract excerpt

Lung cancer is frequently caused by activating mutations in the epidermal growth factor receptor (EGFR). Allosteric EGFR inhibitors offer promise as the next generation of therapeutics, as they are unaffected by common ATP-site resistance mutations and synergize with the drug osimertinib. Here, we examine combinations of ATP-competitive and allosteric inhibitors to better understand the molecular basis for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Triphosphate
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to EGFR gene

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 35534503
DOI: 10.1038/s41467-022-30258-y
PMCID: PMC9085736

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors.PMID 35534503Read ↗

Deciphering the T790M/L858R-Selective Inhibition Mechanism of an Allosteric Inhibitor of EGFR: Insights from Molecular Simulations.Semantic proximity Read ↗

Uncovering the Structural and Binding Insights of Dual Inhibitors Simultaneously Targeting Two Distinct Sites on EGFR Kinase.Semantic proximity Read ↗

Insights into the negative regulation of EGFR upon the binding of an allosteric inhibitor.Semantic proximity Read ↗

Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent "Type V" Kinase Inhibitors.Semantic proximity Read ↗

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.Semantic proximity Read ↗

Molecular Design of a “Two-in-One” Orthosteric-Allosteric Chimeric Mutant Selective EGFR InhibitorSemantic proximity Read ↗

Design of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites.Semantic proximity Read ↗

A Constitutive EGFR Kinase Dimer to Study Inhibitor Pharmacology.Semantic proximity Read ↗

Orthoallosteric EGFR-TKIs: A New Paradigm in NSCLC Treatment Strategy Targeting the C797S Mutation.Semantic proximity Read ↗

In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile.Semantic proximity Read ↗

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.Semantic proximity Read ↗

EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidenceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.